Moringa Sponsor Reports 17.7% Stake After Disputed Debt Conversions
SLXN is trading near its 52-week low of $0.236 (9.4% above the low).
Summary
Moringa Sponsor reports a 17.7% stake in Silexion after multiple disputed debt-to-equity conversions, including a September 16 conversion at $0.37 per share. The sponsor disputes the validity of all conversions and has sued the company.
Key Events · Ownership and Investor Activity · SLXN
-
17.7% Stake Reported
Moringa Sponsor, LP and affiliates report beneficial ownership of 1,954,056 ordinary shares, representing 17.7% of Silexion's outstanding shares.
-
Disputed Debt Conversions
The stake increase stems from multiple conversions of a $3.4 million promissory note, including $206,464 converted into 562,266 shares at $0.37 per share on September 16, 2026.
-
Validity of Conversions Challenged
Moringa Sponsor expressly disputes the validity of all conversions and does not concede beneficial ownership, alleging breaches of the note's conversion conditions.
-
Lawsuit Against Silexion
Moringa Sponsor filed a claim on June 22, 2026 against Silexion and two senior officers, seeking to void the conversions, declare an event of default, and obtain damages.
Analysis · SLXN · Life Sciences
Moringa Sponsor, LP and affiliates now report beneficial ownership of 1,954,056 ordinary shares (17.7% of class), up from prior filings, driven by a series of debt-to-equity conversions under a $3.4 million promissory note. The most recent conversion on September 16, 2026 converted $206,464 into 562,266 shares at $0.37 per share. Critically, Moringa Sponsor expressly disputes the validity of all conversions and has filed a claim against Silexion and two senior officers alleging breaches of the note's conversion conditions. This dispute creates uncertainty over the actual share count and could lead to a court order voiding the conversions or requiring repayment of the full debt, which would materially impact Silexion's capital structure and the ownership stakes of existing shareholders.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.